Massive Bio introduces GPT4-powered chatbots, AskFiona AI and DrArturo AI, revolutionizing oncology clinical trials and patient care.
Massive Bio, a leader in personalized oncology solutions, recently unveiled its GPT4 AI chatbots, AskFiona AI and DrArturo AI, at ASCO 2023, marking a significant leap in cancer care and research. These AI-driven tools are set to transform patient-provider engagement and advance global oncology research.
The new platform is central to transforming clinical trials. It elevates Massive Bio’s existing SYNERGY-AI Clinical Trial Matching Solution, promising a new era in personalized oncology solutions. By incorporating these chatbots, Massive Bio aims to empower patients, enable healthcare consumerization, and lessen reliance on hospital-specific healthcare systems, leveraging the latest in generative AI technology.
AskFiona AI, an advanced AI chatbot, guides patients through the complexities of clinical trials, clarifying trial purposes, processes, and patient eligibility. This fosters clear, informed decision-making for cancer patients. Complementing this, DrArturo AI serves as a vital virtual oncology tool for providers, including oncologists and hematologists, offering detailed, personalized information about clinical trials, treatment details, and insurance acceptance.
Dr. Arturo Loaiza Bonilla, Co-founder and CMO of Massive Bio, highlighted that DrArturo AI is invaluable for site investigators and research coordinators, providing detailed study explanations, responding to protocol-related queries, and ensuring a continuous flow of crucial information. This capability enhances patient care and accelerates research.